Furthermore, data from a thorough study of 1135 breast cancer patients with up to a 22-year follow-up demonstrated the predictive value of immunoexpression for the combination of Securin and Separase, regulatory proteins involved in the metaphase/anaphase transition. This evidence concerns the gene ESPL1 and breast cancer.